These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3528778)

  • 1. Recurrent "flare" of dermatitis herpetiformis after cytotoxic therapy for malignant lymphoma.
    Gottlieb D; Commens C
    Med J Aust; 1986 Sep; 145(5):241. PubMed ID: 3528778
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interstitial pneumonia in patients treated with VACOP-B therapy for malignant lymphoma].
    Sakai C; Goto S; Nakaseko C; Kumagai K; Takagi T
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):423-6. PubMed ID: 9492839
    [No Abstract]   [Full Text] [Related]  

  • 3. [Vocal cord paralysis secondary to vincristine].
    Nafil H; Tazi I; Mahmal L
    Rev Neurol (Paris); 2012 May; 168(5):464-5. PubMed ID: 22387202
    [No Abstract]   [Full Text] [Related]  

  • 4. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Fisher RI
    Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
    [No Abstract]   [Full Text] [Related]  

  • 5. [Picture in clinical hematology].
    Hatsuse M; Shimazaki C; Yumiba T
    Rinsho Ketsueki; 2013 Jan; 54(1):1. PubMed ID: 24015417
    [No Abstract]   [Full Text] [Related]  

  • 6. Hope for very elderly patients with diffuse large B-cell lymphoma.
    Ribera JM
    Lancet Oncol; 2011 May; 12(5):412-3. PubMed ID: 21482185
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Connors JM
    Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.
    Guidez S; Lacotte-Thierry L; Tomowiak C; Princet I; Dreyfus B; Olivier G; Fleck E; Corby A; Motard C; Barrier J; Machet A; Le Dû K; Debiais-Delpech C; Chabin M; Leleu X; Guilhot J; Delwail V
    Br J Haematol; 2019 Sep; 186(6):e175-e178. PubMed ID: 31309541
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lingua villosa nigra after chemotherapy].
    Lkhoyaali S; Errihani H
    Pan Afr Med J; 2014; 18():69. PubMed ID: 25400836
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidden superpower.
    McGuirt J
    JAAPA; 2019 May; 32(5):66. PubMed ID: 31033720
    [No Abstract]   [Full Text] [Related]  

  • 13. HBV reactivation in immunosuppressed patients: prevention or containment?
    Ludwig E
    Hepatology; 2014 Jun; 59(6):2062-4. PubMed ID: 24753022
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
    Hosoi M; Yamamoto G; Imai Y; Kurokawa M
    Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
    Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
    Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
    [No Abstract]   [Full Text] [Related]  

  • 16. Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma.
    Matsuo T; Tanaka T; Yano T
    J Clin Exp Hematop; 2018 Dec; 58(4):180-183. PubMed ID: 30416173
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
    Pariente A
    Rev Prat; 2014 Mar; 64(3):324. PubMed ID: 24851363
    [No Abstract]   [Full Text] [Related]  

  • 19. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
    Tadmor T; McLaughlin P; Polliack A
    Leuk Lymphoma; 2010 May; 51(5):737-8. PubMed ID: 20367567
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.